Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate

被引：18

作者：

Bailit, Jennifer L. ^{[1
]}

Votruba, Mark E.

机构：

[1] Case Western Reserve Univ, Weatherhead Sch Management, Dept Obstet & Gynecol, Div Maternal Fetal Med, Cleveland, OH 44106 USA

[2] Case Western Reserve Univ, Weatherhead Sch Management, Ctr Hlth Care Res & Policy, Cleveland, OH 44106 USA

[3] Case Western Reserve Univ, Weatherhead Sch Management, Metrohlth Med Ctr, Cleveland, OH 44106 USA

[4] Case Western Reserve Univ, Weatherhead Sch Management, Dept Econ, Cleveland, OH 44106 USA

来源：

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 2007年 / 196卷 / 03期

关键词：

17 alpha hydroxyprogesterone caproate; low birthweight; neonatal medical costs; preterm birth;

D O I：

10.1016/j.ajog.2006.12.021

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: This study was undertaken to assess the impact of 17 alpha hydroxyprogesterone caproate treatment on future medical costs for expectant mothers with a prior spontaneous preterm birth. Study design: Data on the costs of preterm birth were combined with published data on the effectiveness of 17 alpha hydroxyprogesterone caproate to produce estimates of the effect of treatment on expected future direct medical costs. These estimates were compared with an estimate of the cost of a typical 17 alpha hydroxyprogesterone caproate treatment regimen to estimate the net savings per treated woman. Results: Treatment is estimated to reduce initial neonatal hospitalization costs by $3800 per woman treated with 17 alpha hydroxyprogesterone caproate. Expected lifetime medical costs (discounted) of treated infants are estimated to decline $15,900. Conclusions: Treating expectant mothers with a prior spontaneous preterm birth with 17 alpha hydroxyprogesterone caproate generates future medical cost savings that substantially exceed the cost of treatment. If this population were universally treated with 17 alpha hydroxyprogesterone caproate, discounted lifetime medical costs of their offspring could be reduced by more than $2.0 billion annually. © 2007 Mosby, Inc. All rights reserved.

引用

页码：219 / 220

页数：2

共 25 条

[11]

Use of progesterone to reduce preterm birth, (2003)

[12]

Petrini J., Callaghan W., Klebanoff M., Et al., Estimated effect of 17 alpha hydroxyprogesterone caproate on preterm birth in the United States, Obstet Gynecol, 105, pp. 267-272, (2005)

[13]

Lewit E., Baker L., Corman H., Shiono P., The direct cost of low birth weight, Future Child, 5, pp. 35-56, (1995)

[14]

Dodd J.M., Crowther C.A., Cincotta R., Flenady V., Robinson J.S., Progesterone supplementation for preventing preterm birth: a systematic review and meta-analysis, Acta Obstet Gynecol Scand, 84, pp. 526-533, (2005)

[15]

Yemini M., Borenstein R., Dreazen E., Et al., Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate, Am J Obstet Gynecol, 151, pp. 574-577, (1985)

[16]

Johnson J.W., Austin K.L., Jones G.S., Davis G.H., King T.M., Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor.[see comment], N Engl J Med, 293, pp. 675-680, (1975)

[17]

Papiernik-Berkauer E., Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d-accouchment premature edition. Schering, Serie IV, 3, pp. 65-68, (1970)

[18]

LeVine L., Habitual abortion: a controlled study of progestational therapy, West J Surg Obstet Gynecol, 72, pp. 30-36, (1964)

[19]

Hartikainen-Sorri A.L., Kauppila A., Tuimala R., Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy, Obstet Gynecol, 56, pp. 692-695, (1980)

[20]

Hauth J.C., Gilstrap III L.C., Brekken A.L., Hauth J.M., The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population, Am J Obstet Gynecol, 146, pp. 187-190, (1983)

← 1 2 3 →